BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.verified

BML.WA

Price:

$5.8

Market Cap:

$267.52M

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topi...[Read more]

Industry

Biotechnology

IPO Date

2011-07-29

Stock Exchange

WSE

Ticker

BML.WA

The PE Ratio as of December 2025 (TTM) for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) is 52.73

According to BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.’s latest financial reports and current stock price. The company's current PE Ratio is 52.73. This represents a change of -185.06% compared to the average of -61.99 of the last 4 quarters.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) Historical PE Ratio (quarterly & annually)

How has BML.WA PE Ratio performed in the past?

The mean historical PE Ratio of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. over the last ten years is 52.37. The current 52.73 PE Ratio has changed 9.97% with respect to the historical average. Over the past ten years (40 quarters), BML.WA's PE Ratio was at its highest in in the September 2020 quarter at 2.77K. The PE Ratio was at its lowest in in the September 2021 quarter at -272.56.

Quarterly (TTM)
Annual

Average

52.37

Median

52.64

Minimum

-2.48

Maximum

142.67

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 377.32%

Maximum Annual PE Ratio = 142.67

Minimum Annual Increase = -6738.17%

Minimum Annual PE Ratio = -2.48

Quarterly (TTM)
Annual
YearPE RatioChange
202442.22-33.04%
202363.05-2.10%
202264.41-2.36%
202165.96-47.51%
2020125.67377.32%
201926.33-1442.02%
2018-1.96-101.38%
2017142.67-6738.17%
2016-2.15-13.47%
2015-2.48-100.42%

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) Average PE Ratio

How has BML.WA PE Ratio performed in the past?

The current PE Ratio of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

56.56

5-year avg

72.26

10-year avg

52.37

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) PE Ratio vs. Peers

How is BML.WA’s PE Ratio compared to its peers?

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.’s PE Ratio is greater than KGHM Polska Miedz S.A. (19.17), greater than Allegro.eu S.A. (30.05), greater than Polski Koncern Naftowy ORLEN Spólka Akcyjna (10.15), greater than Powszechny Zaklad Ubezpieczen S.A. (9.24), less than CD Projekt S.A. (54.79),

Build a custom stock screener for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s PE Ratio?

How is the PE Ratio calculated for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA)?

What is the highest PE Ratio for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA)?

What is the 3-year average PE Ratio for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA)?

What is the 5-year average PE Ratio for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA)?

How does the current PE Ratio for BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML.WA) compare to its historical average?